bendamustine hydrochloride has been researched along with Leukemia, Myeloid, Acute in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W | 1 |
| Bar, MH; Bartlett, NL; Cabanillas, F; Chen, Z; Cheson, BD; Dodds, AJ; Ellis, T; Friedberg, JW; Ganjoo, KN; Herst, J; Joyce, R; LaCasce, AS; Lemieux, B; Leonard, JP; Martin, P; Montgomery, PG; Pressnail, B; Rajguru, SA; Robinson, KS; Smith, MR; Szer, J; van der Jagt, RH; VanderWalde, A; Williams, M | 1 |
| He, X; Huang, J; Huang, S; Huang, X; Jin, J; Li, C; Li, F; Li, X; Ma, Z; Pan, J; Wang, J; Wang, Y; Xu, Y; Yan, X; Yu, M; Yu, Y; Zhou, Y | 1 |
| de Fabritiis, P; Fratoni, S; Giovannini, M; Niscola, P; Palombi, M; Perrotti, A; Scaramucci, L; Tendas, A; Trawinska, MM | 1 |
| Campeny-Najara, A; García, DK; García-Muñoz, R; Merchante-Andreu, M; Rabasa, P; Roldán-Galiacho, V | 1 |
| Ahn, HS; Aplenc, R; Bensen-Kennedy, D; Brown, P; Cho, B; Frankel, L; Fraser, C; Harker-Murray, P; Kirov, I; Megason, G; Munteanu, M; Weaver, J | 1 |
| Appelbaum, FR; Becker, PS; Boehm, A; Dean, C; Deeg, HJ; Estey, EH; Hendrie, PC; Lionberger, JM; Mawad, R; Ostronoff, F; Pagel, JM; Sandhu, VK; Scott, BL; Shadman, M; Shannon-Dorcy, K; Walter, RB; Xie, H | 1 |
| Bond, M; Darwish, M; Grasela, T; Hellriegel, E; Megason, G; Phillips, L; Robertson, P | 1 |
| Chen, S; Ge, Q; Guo, D; Li, S; Liu, S; Qiu, S; Rao, Q; Wang, J; Wang, M; Wang, Y; Wei, H; Xing, H; Yu, J | 1 |
3 trial(s) available for bendamustine hydrochloride and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Nitrogen Mustard Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2014 |
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cohort Studies; Female; Hospitalization; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Outpatients; Treatment Outcome | 2014 |
Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Bayes Theorem; Bendamustine Hydrochloride; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrogen Mustard Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Young Adult | 2014 |
6 other study(ies) available for bendamustine hydrochloride and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Topics: Animals; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; DNA Damage; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Vorinostat; Xenograft Model Antitumor Assays | 2020 |
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Disease-Free Survival; Female; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Rituximab; Time Factors; Treatment Outcome | 2017 |
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bendamustine Hydrochloride; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line; Disease Models, Animal; Drug Synergism; Female; Gene Expression; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Female; Frail Elderly; Humans; Leukemia, Myeloid, Acute; Lymphoma, Large B-Cell, Diffuse; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2013 |
Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Nitrogen Mustard Compounds; Rituximab | 2014 |
A novel SAHA-bendamustine hybrid induces apoptosis of leukemia cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice | 2015 |